Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19 Disease

Fatma Burcu Belen Apak1, Gulbahar Yuce2, Deniz Ilhan Topcu3

  • 1Department of Pediatric Hematology and Oncology, Baskent University Medical Faculty, Sehit Temel Kuguoglu Street No 24, 06490 Bahcelievler/Ankara, Turkey.

Insights

COVID-19 coagulopathy involves distinct hemostatic changes, including endothelial dysfunction and impaired fibrinolysis. Early intervention with anticoagulation may improve outcomes and prevent ICU admission for severe cases.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • COVID-19 is associated with coagulopathy and thrombosis, but its pathogenesis remains unclear.
  • Understanding hemostatic alterations is crucial for managing hospitalized patients.

Purpose of the Study:

  • To evaluate hemostatic and inflammatory parameters in hospitalized COVID-19 patients.
  • To determine if these parameters can differentiate between intensive care unit (ICU) and non-ICU patients.

Main Methods:

  • Prospective case-control study of 51 hospitalized COVID-19 patients and 21 controls.
  • Analysis of various hemostatic markers (e.g., fibrinogen, D-dimer, EPCR, TPA) and inflammatory markers at admission.
  • Comparison of parameters between ICU and non-ICU groups, and survivors versus non-survivors.

Main Results:

  • COVID-19 patients showed increased fibrinogen, PT, EPCR, D-dimer, selectins, PAI-1, and TPA, with decreased SFMC, PDMP, antithrombin, and protein C compared to controls.
  • Tissue plasminogen activator (TPA) levels significantly differed between ICU and non-ICU patients.
  • Findings suggest distinct coagulopathy with early endothelial involvement and fibrinolytic shutdown.

Conclusions:

  • COVID-19 associated coagulopathy differs from sepsis-induced DIC.
  • Early endothelial function restoration may prevent ICU progression.
  • Consider early LMWH therapy for COVID-19 patients to improve endothelial function and anticoagulation, pending bleeding risk assessment.

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
809
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
19
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K